Literature DB >> 33244601

Rituximab for the treatment of systemic sclerosis-interstitial lung disease.

Michael Hughes1, Christopher P Denton2, Dinesh Khanna3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33244601     DOI： 10.1093/rheumatology/keaa675

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  2 in total

1.  Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis.

Authors:  Paul Gressenberger; Philipp Jud; Gabor Kovacs; Sonja Kreuzer; Hans-Peter Brezinsek; Katharina Guetl; Viktoria Muster; Ewald Kolesnik; Albrecht Schmidt; Balazs Odler; Gabriel Adelsmayr; Peter Neumeister; Luka Brcic; Sabine Zenz; Kurt Weber; Thomas Gary; Marianne Brodmann; Winfried B Graninger; Florentine C Moazedi-Fürst
Journal:  J Pers Med       Date:  2021-06-25

2.  [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)].

Authors:  Katharina Buschulte; Anna-Maria Hoffmann-Vold; Rucsan Dra Dobrota; Philipp Höger; Andreas Krause; Michael Kreuter
Journal:  Z Rheumatol       Date:  2021-09-10       Impact factor: 1.372
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.